Immune-Onc Therapeutics, Inc. Overview
Pro stress-test →Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutic antibodies that target myeloid checkpoints in the tumor microenvironment to overcome immune resistance in cancer patients. Founded in 2016 and headquartered in Palo Alto, the company focuses on first-in-class myeloid checkpoint inhibitors with a differentiated approach to cancer immunotherapy.
Strategic Profile
Pro stress-test →The company has a focused pipeline targeting Leukocyte Immunoglobulin-like Receptor subfamily B (LILRB) myeloid checkpoints, with lead programs IO-108 and IO-202 advancing through clinical trials. Immune-Onc has secured strategic partnerships with leading biopharmaceutical companies including BeiGene and Regeneron, and maintains research collaborations with top-tier institutions including Memorial Sloan Kettering Cancer Center.
Competitive Landscape
Pro stress-test →Immune-Onc competes in the immuno-oncology space alongside companies developing checkpoint inhibitors and cellular immunotherapies. Direct competitors include Jazz Pharmaceuticals, Sana Biotechnology, and Kite Pharma. However, the company's specific focus on LILRB myeloid checkpoints differentiates it from the broader PD-1/PD-L1 checkpoint inhibitor market dominated by larger pharmaceutical companies.
Industry Context
Immune-Onc Therapeutics, Inc. operates in Myeloid checkpoint inhibitors and immuno-oncology antibodies.
Key facts
Founded: 2016 · Headquarters: Palo Alto, US · Employees: 13